Table 4. Summary of clinicopathologic data of patients with breast cancer.
| Characteristics | Patients (815) | ||
|---|---|---|---|
| No. (%) | |||
| age at diagnosis | median | 62.2 yrs. | |
| < 55 yrs. | 270 | (33.1) | |
| >/= 55 yrs. | 545 | (66.9) | |
| T stage (primary tumor) | pT1 | 420 | (51.5) |
| pT2 | 349 | (42.8) | |
| pT3 | 39 | (4.8) | |
| pT4 | 7 | (0.9) | |
| N stage (lymph node) | N0 | 501 | (61.5) |
| N1 | 231 | (28.3) | |
| N2 | 51 | (6.3) | |
| N3 | 3 | (3.9) | |
| M stage (distant metastases) | M0 | 815 | (100.0) |
| M1 | 0 | (0.0) | |
| lymph vessel invasion | L0 | 592 | (72.6) |
| L1 | 223 | (27.4) | |
| grade | G1 | 94 | (11.5) |
| G2 | 508 | (62.3) | |
| G3 | 211 | (26.2) | |
| histology | ductal invasive | 647 | (79.4) |
| lobular invasive | 123 | (15.1) | |
| other | 45 | (5.5) | |
| HR-status | negative | 118 | (14.5) |
| positive | 697 | (85.5) | |
| ER-status | negative | 126 | (15.5) |
| positive | 689 | (84.5) | |
| PR-status | negative | 247 | (30.3) |
| positive | 568 | (69.7) | |
| HER2-status | negative | 702 | (86.1) |
| positive | 113 | (13.9) | |
Abbreviations: HR – hormone receptor; ER – estrogen receptor; PR – progesterone receptor; HER2 – human epidermal growth factor receptor 2.